Efficacy of antiviral therapy and host-virus interactions visualised using serial liver sampling with fine-needle aspirates.

ABSTRACT:

Background & aims

Novel therapies for chronic hepatitis B (CHB), such as RNA interference, target all viral RNAs for degradation, whereas nucleoside analogues are thought to block reverse transcription with minimal impact on viral transcripts. However, limitations in technology and sampling frequency have been obstacles to measuring actual changes in HBV transcription in the liver of patients starting therapy.

Methods

We used elective liver sampling with fine-needle aspirates (FNAs) to investigate the impact of treatment on viral replication in patients with CHB. Liver FNAs were collected from patients with CHB at baseline and 12 and 24 weeks after starting tenofovir alafenamide treatment. Liver FNAs were subjected to single-cell RNA sequencing and analysed using the Viral-T

SUBMITTER: Kim SC 

PROVIDER: S-EPMC10432215 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature